[1]曹粒辉　刘　晓　戴永建　唐振刚　刘　岳.慢性硬膜下血肿脂联素和基底膜蛋白多糖的表达[J].中国临床神经外科杂志,2021,26(04):278-280.[doi:10.13798/j.issn.1009-153X.2021.04.016]
　CAO Li-hui,LIU Xiao,DAI Yong-jian,et al.Expression of adiponectin and perlecan in chronic subdural hematoma[J].,2021,26(04):278-280.[doi:10.13798/j.issn.1009-153X.2021.04.016]
点击复制

慢性硬膜下血肿脂联素和基底膜蛋白多糖的表达()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
26
期数:
2021年04期
页码:
278-280
栏目:
实验研究
出版日期:
2021-04-25

文章信息/Info

Title:
Expression of adiponectin and perlecan in chronic subdural hematoma
文章编号:
1009-153X（2021）04-0278-03
作者:
曹粒辉　刘　晓　戴永建　唐振刚　刘　岳
442000 湖北十堰，锦州医科大学湖北医药学院研究生培养基地（曹粒辉）；441000 湖北襄阳，湖北医药学院附属襄阳市第一人民医院神经外科（刘　晓、刘　岳）；442000 湖北十堰，湖北医药学院附属十堰市人民医院神经外科（戴永建、唐振刚）
Author(s):
CAO Li-hui1;  LIU Xiao2;  DAI Yong-jian3;  TANG Zhen-gang3;  LIU Yue2.
1. Postgraduate Training Base of Hubei University of Medicine, Jinzhou Medical University, Shiyan 442000, China; 2. Department of Neurosurgery, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, China; 3. Department of Neurosurgery, Shiyan People’s Hospital, Hubei University of Medicine, Shiyan 442000, China
关键词:
慢性硬膜下血肿; 脂联素; 基底膜蛋白多糖
Keywords:
Chronic subdural hematoma;  Adiponectin;  Perlecan
分类号:
R 651.1+5; Q 786
DOI:
10.13798/j.issn.1009-153X.2021.04.016
文献标志码:
A
摘要:
目的 探讨慢性硬膜下血肿脂联素（APN）、基底膜蛋白多糖（PL）的表达变化。方法 2019年5月至2020年5月钻孔引流术治疗CSDH共32例，所有病人入院后均服用阿托伐他汀钙片，直至复查CT示血肿完全吸收。术前、术后3 d、术后3周各取静脉血5 ml，术中采集血肿液5 ml，采用酶联免疫吸附法检测APN和PL的浓度。结果 血肿液APN浓度[（12.3±1.9）ng/ml]较外周血[（13.8±0.7）ng/ml]明显降低（P<0.05），而PL浓度[（10.9±4.3）ng/ml]较外周血[（7.6±2.3）ng/ml]明显增高（P<0.05）。术后3 d外周血APN浓度[（14.1±0.7）ng/ml]较术前无明显变化（P>0.05），术后3周外周血APN浓度[（15.3±0.8）ng/ml]较术前明显增高（P<0.05）。血肿液APN浓度与血肿液PL浓度呈明显负相关（r=-0.585，P<0.01）；血肿液APN浓度与血肿量呈明显负相关（r=-0.486，P<0.01）；血肿液PL浓度与血肿量呈明显正相关（r=0.557，P<0.01）。结论 本文结果提示APN和PL在CSDH发生、发展过程中具有一定作用，APN可作为CSDH阿托伐他汀治疗反应的评估指标。
Abstract:
Objective To explore the expression of adiponectin (APN) and perlecan (PL) in the chronic subdural hematoma (CSDH). Methods The hemotoma and peripheral blood levels of APN and PL were detected in 32 patients with CSDH who underwent drilling drainage from May 2019 to May 2020 and received atorvastatin calcium tablets until the hemotomas were completely absorbed using the enzyme-linked immunosorbent assay. Results The APN concentration in hematoma [(12.3±1.9) ng/ml] was significantly lower that [(13.8±0.7) ng/ml] in peripheral blood before the operation (P<0.05), and PL concentration in hemotoma [(10.9±4.3) ng/ml] was significantly higher than that [(7.6±2.3) ng/ml] in peripheral blood before the operation (P<0.05). The APN concentration in peripheral blood 3 days after the surgery [(14.1±0.7) ng/ml; P>0.05] did not significantly changed and significantly increased 3 weeks after the surgery [(15.3±0.8) ng/ml; P<0.05] compared with before the surgery. The hematoma APN concentration was significantly negatively correlated with the hematoma PL concentration (r=0.585, P<0.01). The concentration of hematoma APN was significantly negatively correlated with the amount of hematoma (r=-0.486, P<0.01). The hematoma PL concentration was significantly positively correlated with the amount of hematoma (r=0.557, P<0.01). Conclusions Our results suggest that APN and PL have a certain role in the pathogenesis and development of CSDH, and the APN can be used as an assessment indicator of atorvastatin treatment for the CSDH.

参考文献/References:

[1] Wada M, Yamakami I, Higuchi Y, et al. Influence of anti-platelet therapy on postoperative recurrence of chronic subdural hematoma: a multicenter retrospective study in 719 patients [J]. Clin Neurol Neurosurg, 2014, 120: 49-54.
[2] Torihashi K, Sadamasa N, Yoshida K, et al. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases [J]. Neurosurgery, 2008, 63(6): 1125-1129, 1129.
[3] Schwarz F, Loos F, Dunisch P, et al. Risk factors for reope-ration after initial burr hole trephination in chronic subduralhematomas [J]. Clin Neurol Neurosurg, 2015, 138: 66-71.
[4] Melrose J. Perlecan, a modular instructive proteoglycan with diverse functional properties [J]. Int J Biochem Cell Biol, 2020, 128: 105849.
[5] Nguyen T. Adiponectin: role in physiology and pathophysio-logy [J]. Int J Prev Med, 2020, 11: 136.
[6] Edlmann E, Giorgi-Coll S, Whitfield PC, et al. Pathophysio-logy of chronic subdural haematoma: inflammation, angio-genesis and implications for pharmacotherapy [J]. J Neuro-inflammation, 2017, 14(1): 108.
[7] Takei J, Tanaka T, Yamamoto Y, et al. Significantly high concentrations of vascular endothelial growth factor in chronic subdural hematoma with trabecular formation [J]. Clin Neurol Neurosurg, 2021, 202: 106458.
[8] Yang Y, Hu W, Jiang S, et al. The emerging role of adipo-nectin in cerebrovascular and neurodegenerative diseases [J]. Biochim Biophys Acta, 2015, 1852(9): 1887-1894.
[9] Chen B, Liao WQ, Xu N, et al. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action [J]. Brain Res, 2009, 1273: 129-137.
[10] Koopal C, Geerlings MI, Muller M, et al. The relation between apolipoprotein E (APOE) genotype and peripheral artery disease in patients at high risk for cardiovascular disease [J]. Atherosclerosis, 2016, 246: 187-192.
[11] Nakamura K, Ikeuchi T, Nara K, et al. Perlecan regulates pericyte dynamics in the maintenance and repair of the blood-brain barrier [J]. J Cell Biol, 2019, 218(10): 3506-3525.
[12] Douglass S, Goyal A, Iozzo RV. The role of perlecan and endorepellin in the control of tumor angiogenesis and endo-thelial cell autophagy [J]. Connect Tissue Res, 2015, 56(5): 381-391.
[13] Kinsella MG, Tran PK, Weiser-Evans MC, et al. Changes in perlecan expression during vascular injury: role in the inhi-bition of smooth muscle cell proliferation in the late lesion[J]. Arterioscler Thromb Vasc Biol, 2003, 23(4): 608-614.
[14] Farach-Carson MC, Warren CR, Harrington DA, et al. Bor-der patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders [J]. Matrix Biol, 2014, 34: 64-79.
[15] Lord M S, Tang F, Rnjak-Kovacina J, et al. The multifacet-ed roles of perlecan in fibrosis [J]. Matrix Biol, 2018, 68-69: 150-166.
[16] Katano H, Kamiya K, Mase M, et al. Tissue plasminogen activator in chronic subdural hematomas as a predictor of recurrence [J]. J Neurosurg, 2006, 104(1): 79-84.
[17] Jiang R, Zhao S, Wang R, et al. Safety and efficacy of atorv-astatin for chronic subdural hematoma in chinese patients: a randomized clinical trial [J]. JAMA Neurol, 2018, 75(11): 1338-1346.
[18] Chrusciel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentra-tions: a systematic review and meta-analysis of 43 rando-mized controlled trial arms [J]. Atherosclerosis, 2016, 253: 194-208.
[19] Wang D, Wang H, Xu M, et al. The effect of atorvastatin on recurrence of chronic subdural hematoma after novel YL-1 puncture needle surgery [J]. Clin Neurol Neurosurg, 2021,202: 106548.
[20] Yamashita Y, Nakada S, Yoshihara T, et al. Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolismwith dynamic changes in adipose tissue and skeletal muscle [J]. Sci Rep, 2018, 8(1): 7766.

相似文献/References:

[1]庞陆军　张恒柱　李育平　严正村　王杏东　魏　民.慢性硬膜下血肿术前影像学分型和手术治疗[J].中国临床神经外科杂志,2016,(02):101.[doi:10.13798/j.issn.1009-153X.2016.02.014]
[2]王林风　郑华山　操　廉　李庆阳　贾俊峰　丁　磊　张　武.钻孔引流术治疗慢性硬膜下血肿90例[J].中国临床神经外科杂志,2016,(02):109.[doi:10.13798/j.issn.1009-153X.2016.02.018]
[3]王　斌　杨秀莹.高位颅骨钻孔引流术治疗慢性硬膜下血肿[J].中国临床神经外科杂志,2016,(02):115.[doi:10.13798/j.issn.1009-153X.2016.02.021]
[4]孙成法　姜　华　褚荣涛　金　科.671例慢性硬膜下血肿的临床分析[J].中国临床神经外科杂志,2016,(01):42.[doi:10.13798/j.issn.1009-153X.2016.01.015]
[5]陈　新　张传玲　王伟功.锥颅引流术与钻孔冲洗引流术治疗慢性硬膜下血肿的疗效对比分析[J].中国临床神经外科杂志,2016,(01):53.[doi:10.13798/j.issn.1009-153X.2016.01.020]
[6]黄海源　颜庆华　张　猛　丁兴进　刘　枫　沈建华　史　俊.慢性硬膜下血肿钻孔引流术中持续冲洗的临床效果[J].中国临床神经外科杂志,2016,(01):55.[doi:10.13798/j.issn.1009-153X.2016.01.021]
[7]曾昭戎.慢性硬膜下血肿钻孔引流术中尿激酶的应用体会[J].中国临床神经外科杂志,2015,(08):491.[doi:10.13798/j.issn.1009-153X.2015.08.017]
[8]李乾锋　吴京雷　杨国平.神经内镜手术治疗慢性硬膜下血肿50例[J].中国临床神经外科杂志,2015,(09):557.[doi:10.13798/j.issn.1009-153X.2015.09.017]
[9]江敦清　宋熙文　陈世文.IL-6和VEGF在慢性硬膜下血肿中的检测及意义[J].中国临床神经外科杂志,2015,(05):287.[doi:10.13798/j.issn.1009-153X.2015.05.010]
　JIANG Dun-qing,SONG Xi-wen,CHEN Shi-wen..Detection of IL-6 and VEGF levels in chronic subdural hematomas and their meanings[J].,2015,(04):287.[doi:10.13798/j.issn.1009-153X.2015.05.010]
[10]盖延廷　贺子建.钻孔引流术与钻孔冲洗术治疗慢性硬膜下血肿疗效的Meta分析[J].中国临床神经外科杂志,2015,(05):293.[doi:10.13798/j.issn.1009-153X.2015.05.012]

备注/Memo

备注/Memo:
通讯作者：刘　岳，E-mail：Liuyue_119@163.com
更新日期/Last Update: 2021-04-25